
|Videos|January 22, 2019
Time Points in the Assessment of MRD
Advertisement
" width="560">Transcript:Mark R. Litzow, MD: Anthony, when do you think we should be measuring MRD?
Anthony S. Stein, MD: I think it also depends which regimen you
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5



































